Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ameloderm
- Development stage
- Unknown
- Lead developer
- PRUDENTIX
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intradermal
01
Overview
Ameloderm is an intradermal recombinant human amelogenin gel developed by Prudentix for the improvement of postoperative scar formation. The active ingredient, recombinant human amelogenin (rAmelX), is an extracellular matrix protein that acts as a physical scaffold and a signaling molecule. It recruits mesenchymal stem cells (MSCs) and pericytes to the wound site, promoting a regenerative healing process and shifting the tissue response away from fibrotic scar formation. Formulated as a thermo-sensitive gel, Ameloderm remains liquid at lower temperatures and transitions into a viscous gel at body temperature, allowing for precise intradermal injection during routine skin lesion excision surgery.
- Brand names
- Ameloderm
- Other names
- rAmelX gelrecombinant human amelogenin gel
Beyond the preview
Go deeper on Ameloderm.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ameloderm.